Multiple myeloma - haematology - SA Health Approved Cancer Chemotherapy Protocol Register

Waldenstrom macroglobulinaemia

Waldenstrom macroglobulinaemia
Protocol Administration at chemotherapy unit level Review Date
Waldenstrom macroglobulinaemia DRC (dexamethasone RITUximab CYCLOPHOSPHamide) Medium August 2024

Multiple myeloma

Multiple myeloma
Protocol Administration at chemotherapy unit level Review Date
AL amyloidosis melphalan and dexamethasone oral Medium Cycle 1. Low Cycle 2 onwards if patient tolerates March 2022
Multiple myeloma and AL amyloidosis CTD (CYCLOPHOSPHamide thalidomide dexamethasone) oral Low February 2023
Multiple myeloma carfilzomib and dexamethasone twice weekly
High cycle 1, Medium cycle 2 onwards if patient tolerates February 2022
Multiple myeloma carfilzomib and dexamethasone weekly
High cycle 1, Medium cycle 2 onwards if patient tolerates February 2022
Multiple Myeloma bortezomib, lenalidomide and dexamethasone (VRd) 21-day protocol
First line treatment of newly diagnosed myeloma patients in place of Vd (bortezomib-dex) or Rd (lenalidomide-dex) where appropriate. For more information on this protocol please contact the SA Health Cancer Drug Committee
Low June 2022
Multiple Myeloma bortezomib, lenalidomide and dexamethasone (VRd) 28-day protocol
First line treatment of newly diagnosed transplant-eligible patients. For more information on this protocol please contact the SA Health Cancer Drug Committee.
Low June 2022
Multiple Myeloma bortezomib, lenalidomide and dexamethasone (VRd) 35-day protocol
First line therapy. This protocol provides a modified VRd (VRd-Lite) which can be more safely delivered to elderly and/or frail newly-diagnosed transplant-ineligible multiple myeloma patients. For more information on this protocol please contact the SA Health Cancer Drug Committee.
Low June 2022
Multiple myeloma CyBorD (CYCLOPHOSPHamide bortezomib dexamethasone) Low February 2022
Multiple myeloma CyBorD (CYCLOPHOSPHamide bortezomib dexamethasone) weekly Low February 2022
Multiple myeloma daratumumab High cycle 1, Medium cycle 2 onwards if patient tolerates August 2024
Multiple myeloma daratumumab maintenance High cycle 1, Medium cycle 2 onwards if patient tolerates August 2020
Multiple myeloma DRd (daratumumab lenalidomide dexamethasone) High cycle 1, Medium cycle 2 onwards if patient tolerates August 2020
Multiple myeloma DT-PACE (dexamethasone thalidomide cISplatin DOXOrubicin CYCLOPHOSPHamide etoposide) High August 2024
Multiple myeloma DVd (daratumumab bortezomib dexamethasone)The SAHCDC has endorsed the use of weekly dosing of Bortezomib (Day 1, 8 and 15) for patients unable/unlikely to tolerate twice weekly dosing”  High cycle 1, Medium cycle 2 onwards if patient tolerates February 2022
Multiple myeloma D-VMP (daratumumab bortezomib melphalan prednisolone) High cycle 1, Medium cycle 2 onwards if patient tolerates August 2020
Multiple myeloma ixazomib lenalidomide and dexamethasone oral Low February 2021
Multiple myeloma lenalidomide and dexamethasone oral Low February 2022
Multiple myeloma lenalidomide maintenance post autologous transplant
Low August 2021
Multiple myeloma MPT (melphalan prednisolone thalidomide) oral Low February 2023
Multiple myeloma pomalidomide and dexamethasone oral Low February 2022
Multiple myeloma PVd (pomalidomide bortezomib and dexamethasone)3 Low August 2021
Multiple myeloma thalidomide and dexamethasone oral Low February 2023

Notes

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Non-formulary drug included in the protocol
  4. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.